AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.11 +1.71%

+$0.04 today

Market cap
$214.74M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.12M

Average 0.32M

ACIU Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

AC Immune S.A.NASDAQ: ACIU

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of CHF 11.74M fell 26.2% year over year, behind the -17.6% change in trailing-twelve-month research & development. Sequentially, it rose 11.4% from the prior quarter. Over 3 fiscal years it compounded at -2.2% a year.

Context

  • Research & development amounted to 1579.5% of revenue in FY2025, up 1350.4 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -26.2% toward the trailing-twelve-month pace of -17.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 11.74M+11.4% QoQ
Last fiscal yearDec 2025
CHF 56.44M-9.8% YoY
LTMMar 2026
CHF 52.18M-17.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.2%——
1 year-9.8%——
3-year CAGR-2.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

CHF · from the income statement

Latest · FY2025
56.44M CHF
Year-over-year change
-9.8%
4-year CAGR
-2.4%

Research & Development vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -17.6% is the 9th highest of 10, against a peer median of +5.0%.
  • Research & development amounts to 1409.6% of revenue for ACIU, versus a peer median of 3625.8%.
ACIU Competitors
Research & Development for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$172.31M USD+17.5%+18.0%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$151.83M USD-11.7%-0.1%489780.6%
CLLSCellectis S.A.LTM Mar 2026$94.68M USD+5.0%-1.4%139.0%
SLNSilence Therapeutics plcLTM Mar 2026$61.84M USD—+24.0%6710.8%
ANROAlto Neuroscience, Inc.LTM Mar 2026$55.94M USD+19.0%+24.4%—
ACIUAC Immune S.A.LTM Mar 2026CHF 52.18M CHF-17.6%-2.2%1409.6%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$49.38M USD+11.3%+45.0%—
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$35.87M USD+29.3%+13.9%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$20.65M USD-58.3%-18.4%—
AMRNAmarin Corporation plcLTM Mar 2026$18.45M USD-6.9%-13.3%8.6%
MREOMereo BioPharma Group plcLTM Mar 2026$18.13M USD-12.8%-16.7%3625.8%
Peer median (excluding ACIU) —+5.0%+6.9%3625.8%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.94M14.8M27.31M3.57M
Cost of Revenue0054.61M62.57M0
Gross Profit03.94M(39.81M)(35.26M)3.57M
Gross Margin—100.0%-268.9%-129.1%100.0%
Research & Development62.28M60.34M54.61M62.57M56.44M
Selling, General & Admin10.88M9.58M10.58M11.43M11.65M
Operating Expenses79.01M74.78M13.82M17.12M72.44M
Depreciation & Amortization2.41M2.36M2.22M2.16M2.5M
EBITDA(70.01M)(68.03M)(51.83M)(48.62M)(67.75M)
EBITDA Margin—-1728.7%-350.2%-178.0%-1896.2%
Operating Income(79.01M)(70.85M)(53.62M)(52.38M)(68.86M)
Operating Margin—-1800.4%-362.3%-191.8%-1927.3%
Interest Income6.49M69K1.04M3.2M1.87M
Interest Expense581K355K176K133K191K
Other Income / Expenses6.02M107K(599K)1.47M(1.58M)
Income Before Tax(72.99M)(70.74M)(54.22M)(50.91M)(70.45M)
Pre-Tax Margin—-1797.7%-366.3%-186.4%-1971.6%
Income Tax Expense3K13K10K3K0
Net Income(73M)(70.75M)(54.23M)(50.92M)(70.45M)
Net Margin—-1798.0%-366.4%-186.4%-1971.6%
EPS (Basic)(0.97)(0.85)(0.64)(0.51)(0.70)
EPS (Diluted)(0.97)(0.85)(0.64)(0.51)(0.70)
Weighted Avg Shares74.95M83.55M84.69M99.69M100.75M
Weighted Avg Shares (Diluted)74.95M83.55M84.69M99.69M100.75M

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.